Asher Biotherapeutics

Asher Biotherapeutics

  • Founded: 2019
  • Location: South SF, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: Solid tumors
  • Drug types: ONC, INF, IMM
  • Lead product: AB248
  • Product link:
  • Funding: $108M B Sep 2021; $55M A Mar 2021
  • Investors: Third Rock, Boxer Capital of Tavistock Group, Invus, Y Combinator, MBC Biolabs

job board

Short description:

IL-2 Therapies

Drug notes:

AB821 Clin0 oncology; AB359 Clin0 viral infection; 4 undisclosed programs RD oncology, autoimmune conditions

Long description:

Asher Biotherapeutics is developing immunotherapies for cancer and other diseases. Immunotherapies are a promising strategy for cancer treatment; however, they indiscriminately act on multiple cell types and thus cause side effects. Asher is pioneering cis-targeting immunotherapies that only activate the immune cell types that drive the desired therapeutic effect. Cis-targeting works by engaing two receptors, an immunomodulatory receptor and a specific surface marker, present on the same immune cell to achieve higher selectivity. Asher is identifying drugs using their cis-targeting platform that can be tailored for different immune cells. Asher’s lead molecule, AB248, specifically activates CD8+ effector T cells and is being investigated against multiple solid tumors.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy